This phase II trial studies how well a shortened course of external beam radiation therapy before surgery works in treating patients with soft tissue sarcoma of the extremities, trunk or retroperitoneum. External beam radiation therapy uses high energy protons to kill cancer cells and shrink tumors. Radiation therapy given before surgery is a standard treatment option for patients with soft tissue sarcomas and is typically delivered in 25 treatments over 5 weeks. However, many sarcoma patients often have to travel great distances for treatment, and even for patients who live nearby, daily treatment for 5 weeks can be a considerable burden. Researchers want to test how well a shortened course of radiation therapy before surgery works in treating patients with soft tissue sarcomas.
Additional locations may be listed on ClinicalTrials.gov for NCT06087861.
Locations matching your search criteria
United States
California
Palo Alto
Stanford Cancer Institute Palo AltoStatus: Active
Contact: Anusha Kalbasi
Phone: 650-723-0914
PRIMARY OBJECTIVE:
I. Evaluate the safety of surgical resection after an abbreviated course of 5-day preoperative radiation in patients with extremity, trunk or retroperitoneal sarcoma.
SECONDARY OBJECTIVE:
I. Evaluate the efficacy and overall safety of an abbreviated course of 5-day preoperative radiation in patients with extremity, trunk or retroperitoneal sarcoma.
OUTLINE:
Patients undergo external beam radiation therapy once daily (QD) for 5 consecutive weekdays. Within 1-6 weeks of completion of radiation therapy, patients undergo surgery. Patients undergo computed tomography (CT) and magnetic resonance imaging (MRI) and may undergo positron emission tomography (PET)/CT throughout the trial. Patients may optionally undergo tissue biopsy during screening and on the trial as well as blood sample collection throughout the trial.
After completion of study treatment, patients are followed up at 3-5 months, then every 6 months for the first 2 years, and then in years 3 and 5.
Lead OrganizationStanford Cancer Institute Palo Alto
Principal InvestigatorAnusha Kalbasi
